Published: March 2015 | Pages: 62 | Format: PDF and Online
This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world’s commercially most successful antibodies (2014 sales of over US$ 6.9 bln). The commercial attractiveness of rituximab has stimulated companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in less regulated countries, but also in phase III studies in Western regulated markets.
The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Contents
1. CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab
2014 Sales of CD20 Antibodies
Marketed CD20 Antibodies & Sales
- Rituxan/MabThera Pipeline & Sales
- Gazyva/ Gazyvaro Pipeline & Sales
- Arzerra Pipeline & Sales
- Zevalin Pipeline & Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
- Rituxan/MabThera (rituximab) Biosimilars
2. Corporate CD20 Antibody Biosimilar & Biosuperior Pipelines